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F I V E  G E N E R A T I O N S  
O F  C H E M I S T S  
AUTOMATH) MACHINERY FOR PHARMACEUTICAL PRODUCTION 
I N  1838, JOAN URIACH 1 FELIU BEGAN HIS FAMILY'S 
INVOLVEMENT IN THE PHARMACEUTICAL INDUSTRY. 
TODAY, MORE THAN A CENTURY AND A HALF LATER, WHAT 
WAS ORIGINALLY A FAMILY BUSINESS HAS GONE ON TO 
BECOME ONE OF THE DRIVING FORCES IN THIS SECTOR IN 
OUR COUNTRY AND AN INTERNATIONAL POINT OF 
REFERENCE. FIVE GENERATIONS OF CHEMISTS SEPARATE 
THE TWO MOMENTS. 
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'le Uriach pharmaceutical group 
Nas founded in 1838 by Joan 
Jriach i Feliu. Since then, in the 
course of a century and a half, what 
was originally a family business has be- 
come a powerful industrial group with a 
share in most of the international mar- 
kets. Today, the Uriach group of firms is 
made up of J.Uriach i Cia. S.A., Bio- 
horm, Dimportex, Urquima and luisa. 
The company as it stands today is the 
result of the determination of the 
group's directors, who at the beginning 
of the sixties decided to step up re- 
search into new medicines. These new 
medicines today account for the larger 
part of the company's turnover. 
The work of the fifth generation of the 
Uriach family in different fields of the 
company's activities is directed at giv- 
ing a new look to the company and 
equipping it to face the challenge of 
new technologies and increasing com- 
petition in the sector. For this reason, 
the group is constantly investing in new 
technology, quality control processes, 
international projection and, especially, 
in research, for which Uriach sets aside 
10 % of its turnover. 
In the field of research, the Uriach 
Group's Research Centre, which act- 
ively collaborates with universities and 
other private research centres, has had 
considerable success in various fields of 
treatment, investigating, developing 
and patenting new pharmaceutical pro- 
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ducts. Work at present is concentrated 
on three fronts, the most advanced of 
which has provided new imidazole deri- 
vatives with antifungal properties for 
the treatment of dermic and vagina1 
mycoses. One of these derivatives, flu- 
trimazol, patented in Europe and North 
America, will soon be put on the market 
with the trade name Micetal. The se- 
cond line of research looks into antqgo- 
nists of the blood platelet activating 
factor, with several medical applica- 
tions.. The third line of research is into 
potassium activators with antihyperten- 
sive andlor bronchodilator action, 
which are of use in the treatment of high 
blood pressure or. asthma. The main 
commercial medicines arising from 
Uriach's own research are as follows: 
Disgren (triflusal), an antithrombotic; 
Flutenal (flupamesone), a dermic corti- 
costeroid; Bronquimucil (brovanexine), 
a mucolytic-expectorant; Staticum (gli- 
sentida), an oral antidiabetic; Disdole 
and Disdole Codeina (fosfosal), an 
analgesic-anti-inflammatory; and Tri- 
metabol (metopinel, an anti-anorexic. 
These products are available in many 
parts of the world, where they are ma- 
nufactured under licence, patents have 
been conceded or the finished product 
is exported. 
Alongside these research brands, 
Uriach markets well-known medicines 
like Dolmen, effervescent analgesic- 
antipyretic-antiflu tablets; Lipograsil, for 
the treatment of obesity; Utabon, a na- 
sal decongestant, and Bioselenium, a 
preparation for dandruff. There is also 
the well known Biodramina, for the pre- 
vention of travel-sickness, a product 
going back to 1952 which is constantly 
being updated and which is also availa- 
ble as chewing gum, a pleasant way of' 
preventing any kind of travel-sickness. 
Uriach also works in veterinary medi- 
cine through its Veterinary Division, 
which produces a wide range of pro- 
ducts for the prevention and treatmeni 
of illnesses affecting farm animals and 
pets -Anorexol, Brovan, Deyanil, Ente- 
romicina, Fugo Misol, Fugo Tenil- as 
well as additives, feed correctors, and 
disinfectants for industrial farm installa- 
tions. 
The active ingredients used by the 
Uriach group in fheir medicinal products 
are prepared by Urquima, the group's 
Fine Chemistry company. Urquima also 
manufactures raw materials for phar- 
maceutical, chemical, veterinary and 
agrochemical firms in this country and 
abroad. 
Aware of the importance of biotechno- 
logy cmd of chiral compounds (medi- 
cines obtained by chemical synthesisl, 
this company devotes part of its time to 
research in these two fields, and has 
already made important advances. 
The Uriach Group applies al1 the GLP 
(Good Laboratory Practices) and GMP 
(Good Manufacturing Practices) regula- 
tions in its manufacturing, production 
and treatment plants. The computeriza- 
tion and automation of the packaging 
plants allows a high production rate 
compatible with pharmaceutical control 
of the manufactured goods. Quality 
controls are also included in every 
stage of production and packaging, 
from raw materials to excipients and 
packaging material. Thanks to the vol- 
ume and quality of production, important 
pharmaceutical companies entrust the 
production of some of their specialities 
to Uriach, especially those known as 
"solid forms". 
Finally, the policy of international ex- 
pansion which Uriach and Urquima have 
been implementing for some decades 
now is orientated towards the Euro- 
pean, American, African and Middle 
Eastern markets. Its constant develop- 
ment is evidence of the acceptation with 
which their medical and pharmaceutical 
products have been received. ¤ 
